Cumulative Impact of Clinical Disease Activity, Biochemical Activity and Psychological Health on the Natural History of Inflammatory Bowel Disease During 8 Years of Longitudinal Follow‐Up
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Christy Riggott und 3 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Mental Disorders. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tillots pharma, Leeds Hospital Charitable Foundation.
Abstract (Originalsprache)
Background
Common mental disorders, including anxiety and depression, are prevalent in patients with inflammatory bowel disease (IBD) and may be associated with adverse outcomes. However, whether increasing psychological co‐morbidity, in combination with disease activity, exerts a cumulative effect on prognosis is uncertain.
Aims
To assess this in a longitudinal follow‐up study.
Methods
We collected baseline demographic and IBD‐related information, clinical activity using disease activity scores and biochemical activity using calprotectin. Patients were grouped according to the presence or absence of disease activity. Patients in remission or with active disease were subgrouped according to the presence or absence of symptoms of a common mental disorder at baseline. We recorded the occurrence of adverse outcomes over 8.1 years, comparing their occurrence across subgroups using Cox regression.
Results
Among 717 participants with clinical activity data and 187 with clinical and biochemical activity data, rates of adverse outcomes increased with both disease activity and increasing psychological co‐morbidity. Rates of flare or glucocorticosteroid prescription, escalation or death were higher with clinical activity (HR 2.89; 95% CI 1.68–4.93 and 2.52; 95% CI 1.55–4.10 and 6.97; 95% CI 2.43–20.0, respectively) or clinical and biochemical activity (HR 7.26; 95% CI 2.86–18.5, 3.62; 95% CI 1.59–8.25 and 57.3; 95% CI 7.58–433, respectively) and two common mental disorders. Rates of hospitalisation (HR 6.20; 95% CI 1.88–20.4) or hospitalisation and/or intestinal resection (HR 7.46; 95% CI 2.41–23.2) were higher with clinical and biochemical activity and two common mental disorders.
Conclusion
Psychological co‐morbidity and active disease have a cumulative adverse impact on IBD prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
- Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
ORCID-Profile: Keeley M Fairbrass, Alexander C Ford
Förderung
- Tillots pharma
- Leeds Hospital Charitable Foundation
Zitieren
APA
Riggott, C., Fairbrass, K. M., Gracie, D. J., & Ford, A. C. (2025). Cumulative Impact of Clinical Disease Activity, Biochemical Activity and Psychological Health on the Natural History of Inflammatory Bowel Disease During 8 Years of Longitudinal Follow‐Up. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70068
Vancouver
Riggott C, Fairbrass KM, Gracie DJ, Ford AC. Cumulative Impact of Clinical Disease Activity, Biochemical Activity and Psychological Health on the Natural History of Inflammatory Bowel Disease During 8 Years of Longitudinal Follow‐Up. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70068
BibTeX
@article{Riggott2025,
author = {Riggott, Christy and Fairbrass, Keeley M and Gracie, David J and Ford, Alexander C},
title = {Cumulative Impact of Clinical Disease Activity, Biochemical Activity and Psychological Health on the Natural History of Inflammatory Bowel Disease During 8 Years of Longitudinal Follow‐Up},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70068}
}
EUVIMED